Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537]: committee papers

Table of Contents

 

01. NICE’s response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD – AbbVie (adalimumab)

02. Consultee comments on the ACD  - Bristol Myers-Squibb (abatacept)

02. Consultee comments on the ACD - Hospira UK (infliximab biosimilar, Inflectra)

02. Consultee comments on the ACD - Napp Pharmaceuticals (infliximab biosimilar, Remsima)

02. Consultee comments on the ACD  - Pfizer (etanercept)

02. Consultee comments on the ACD - Merck Sharp & Dohme Ltd (infliximab, golimumab)

02. Consultee comments on the ACD - Roche (tocilizumab)

02. Consultee comments on the ACD - UCB Pharma Ltd (certolizumab pegol)

02. Consultee comments on the ACD - Arthritis Care

02. Consultee comments on the ACD -  National Rheumatoid Arthritis Society

02. Consultee comments on the ACD - British Society for Rheumatology

02. Consultee comments on the ACD - Royal College of Pathologists

03. Clinical expert comments on the ACD – Choy

04. Consultee and commentator comments on the Executable Model UCB

05. New evidence submitted at ACD stage Hospira

05. New evidence submitted at ACD stage Napp Pharmaceuticals

06. Additional analysis post consultation AG

This page was last updated: 01 September 2015